

A dynamic transmission model for assessing the impact of pneumococcal vaccination

Tufail M Malik^{1*}, Kevin M Bakker¹, Rachel J Oidtman¹, Oluwaseun Sharomi¹, Giulio Meleleo², Robert Nachbar², Elamin H Elbasha¹

¹Merck & Co., Inc., Rahway, NJ, USA

²Wolfram Research, Inc., Champaign, IL, USA

Abstract

Streptococcus pneumoniae (SP) is a bacterial pathogen that kills more than 300,000 children every year across the globe. Multiple vaccines exist that prevent pneumococcal disease, with each vaccine covering a variable number of the more than 100 known serotypes. Due to the high effectiveness of these vaccines, each new pneumococcal conjugate vaccine (PCV) introduction has resulted in a decrease in vaccine-type disease and a shift in the serotype distribution towards non-vaccine types in a phenomenon called serotype replacement. Here, an age-structured compartmental model was created to capture the carriage transmission dynamics of SP and subsequent progression to pneumococcal disease in the presence of vaccines introduced at different times to different age groups. The model incorporates co-colonization and serotype

* tufail.malik@merck.com

20 competition, which drives replacement of the vaccine types by the non-vaccine types. The model
21 was calibrated to historical age- and serotype-specific invasive pneumococcal disease (IPD) data
22 from the United States using vaccine-specific coverage and effectiveness. The calibrated model
23 was then used to project the epidemiological impact of PCV15, a 15-valent pneumococcal
24 vaccine, compared with the status quo vaccination with PCV13 and demonstrated the value of
25 added serotypes in PCV15. Projections revealed that PCV15 would reduce IPD incidence by
26 6.04% (range: 6.01% to 6.06%) over 10 years when compared to PCV13.

27

28 **Introduction**

29 Despite the widespread use of pneumococcal vaccines in the United States (US), *Streptococcus*
30 *pneumoniae* (SP) caused nearly 17,400 cases of invasive pneumococcal disease (IPD) in 2021,
31 and nearly 3,000 associated deaths [1]. Globally the number of deaths in children under 5 is
32 approximately 300,000 [2]. Vaccines are only able to target a portion of the more than 100
33 circulating serotypes (STs) [3], and serotype-specific vaccine effectiveness has been observed.
34 Only a small fraction of these cause majority of disease. Asymptomatic or symptomatic
35 nasopharyngeal carriage (NPC) of SP in an individual, which is relatively common in young
36 children [4], may result in SP transmission to other individuals through person-to-person contact
37 via respiratory droplets. NPC can lead to multiple disease outcomes, including invasive
38 pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), and acute otitis
39 media (AOM) [5]. IPD, which includes meningitis and bacteremic pneumonia, primarily afflicts
40 extremes of ages and those with risk factors [6]. Vaccines play a role in preventing NPC but the
41 necessary immune response is higher than what is required to prevent disease.

42 In the US a pediatric vaccination program with a 7-valent pneumococcal conjugate vaccine
43 (PCV) was introduced in 2000, and building on this composition, a 13-valent PCV was
44 introduced in 2010, followed by a 15-valent vaccine in 2022, and a 20-valent vaccine in 2023.
45 Since 1983, a 23-valent pneumococcal polysaccharide vaccine (PPSV23) had been
46 recommended for all adults 65 years or older. Vaccines targeting additional or different
47 serotypes, along with those based on other technologies, are currently in development. Since the
48 introduction of PCVs, the US has seen a dramatic reduction in IPD across all age groups in
49 vaccine-type (VT) serotypes [6]. There has also been replacement of VTs with non-vaccine types
50 (NVTs) [7]. Globally, there have been higher levels of replacement than those seen in the US,
51 sometimes leading to higher overall incidence levels than the pre-vaccine period (for example in
52 France following PCV13 introduction [8]).

53 Dynamic transmission models (DTMs) have been used extensively to describe the
54 epidemiological and biological dynamics of SP transmission in the presence or absence of
55 vaccination (Table S1 summarizes a review of published models). Here, a DTM was developed
56 to quantify the epidemiological impact of ST-specific and age-based vaccination programs. The
57 model is driven by carriage transmission and assigns each ST into one of 11 serotype classes
58 (STCs, Table S7), which were determined based on their inclusion in different pneumococcal
59 vaccines. Additionally, the model features indirect effects such as herd immunity and
60 competition between ST classes, which determines replacement dynamics following vaccine
61 introduction. The model is flexible, so that it can be used in countries that report disease
62 incidence with different age-groups, incorporated different vaccines into their vaccine schedules
63 (e.g., PCV10), want to examine different vaccination policies, or are interested in other
64 pneumococcal diseases of interest. The model was fitted to historical (2000–2019) US IPD data

65 and the epidemiological impact of the continued use of PCV13 versus implementing PCV15 in
66 the pediatric immunization program was assessed (at the time of this study PCV20 was not yet
67 recommended in peds in the US).

68 **Methods**

69 A model was developed that described SP carriage transmission dynamics and disease
70 progression in the presence of age- and serotype-specific pneumococcal vaccines. Real-world
71 data was used to inform parameters for vaccine effectiveness against disease, coverage rates,
72 duration of protection, carriage clearance rates, and a mixing within and between age groups.
73 Real-world data are lacking for PCV15 given recent introduction. Population data was used to
74 parameterize the demographic aspects of the model.

75 The model was calibrated to national-level IPD data in the US to estimate the probability of SP
76 carriage acquisition per contact, competition between STCs, progression rate from carriage to
77 disease, and vaccine effectiveness against carriage. Disease incidence data were stratified by age
78 and grouped into STCs, based on inclusion in various vaccines (Table S7). With the calibrated
79 model, epidemiological projections were made under different pediatric vaccination scenarios
80 keeping a realistic mix of vaccination regime in the adult population.

81 **Model overview**

82 A deterministic age-structured DTM was constructed to describe pneumococcal carriage
83 transmission dynamics and disease progression in the presence of age- and STC-specific
84 pneumococcal vaccines. In addition to the brief description of the model here, additional details
85 can be found in the Supplementary Appendix. Given the lack of data to parameterize the model

86 for all serotypes and disease outcomes, it was assumed that parameter values were constant
87 across serotypes within the same STC and age group. Each STC was further categorized into 6
88 age groups (0–1, 2–4, 5–17, 18–49, 50–64, and 65+). The model was based on a system of
89 ordinary differential equations and distinguished pneumococcal carriage from disease as well as
90 their vaccine protection status, which varied by age and vaccine type (Fig 1). For example, an
91 unvaccinated person can be either susceptible non-colonized or colonized with up to three STCs.
92 A fraction of infants are born into the unvaccinated susceptible non-colonized compartment and
93 remain there until they are vaccinated, become colonized, or die from causes other than
94 pneumococcal disease. Individuals acquire one or two STCs simultaneously at an age-specific
95 and time-dependent rate (i.e., per capita force of carriage acquisition), progressing from non-
96 colonized status to single or double colonization, from single to double or triple colonization, and
97 from double to triple colonization. It was assumed that an individual could be colonized by up to
98 three STCs concurrently.

Fig 1. Model flowchart. Individuals are born into the non-colonized compartments and can move throughout the system during their lifetime. Upon carriage acquisition, individuals move to the colonized (with a single ST), co-colonized with two STs, or triple-colonized compartments. Colonized individuals can clear carriage of one ST at a time. A proportion of colonized individuals will develop a pneumococcal disease. Vaccination (right arm of flowchart) reduces the chance of carriage acquisition and disease development for vaccine STCs. Detailed model flowchart is provided in Figures S3, S4 and S5.

99 The rate at which uncolonized persons of a given age group acquire SP and become colonized
100 depends on the number and type of contacts, the fraction of colonized, co-colonized, and tri-
101 colonized contacts, and the transmission probability per contact, which varies by age. The
102 number and type of contacts are governed by a conditional probability mixing matrix, where
103 each cell represents the probability of a person of a given age class having contact with a person

104 in another age class (Table S4). Upon recovery, it is assumed that the person does not develop
105 immunity and becomes completely susceptible again.

106 Individuals leave the unvaccinated compartments through cohort and continuous vaccination at
107 given rates and enter the appropriate vaccinated compartment, based on their colonization status.

108 They remain in the vaccinated compartments until they die, acquire SP, or their immunity wanes.

109 Since typical colonization is asymptomatic, individuals can be vaccinated from any of the four
110 (uncolonized, colonized, double colonized, or triple-colonized) unvaccinated compartments.

111 Vaccination reduces the risk of carriage acquisition and disease progression.

112 In the DTM, the rate of acquisition of a second or third STC is reduced due to competition from
113 the currently carried STC(s). The competition parameter is determined by the relationship

114 between the current and the invading STC, and can range from zero competition (i.e.,

115 independence) to complete competition (i.e., exclusion), where the acquisition of the invading

116 STC is completely blocked by the currently carried STC(s).

117 Disease occurrence was modeled using a case-carrier ratio that varies by disease manifestation,

118 age, STC, and vaccine-status. Progression to IPD, AOM, or NBPP were included here, while

119 other manifestations (such as sinusitis) or further classification (such as bacteremia) could be

120 included in future analyses.

121 In addition to the scenarios evaluated here, the model is flexible and can evaluate other vaccine

122 scenarios, such as reducing the vaccination age in adults, having sequential vaccination of

123 different vaccines in an age group, other vaccines, or other potential policy questions.

124 **Model parameters and data sources**

125 Baseline values for demographic, epidemiologic, and vaccine inputs of the model were identified
126 through a targeted search of the published literature and public databases.

127 **Demographic parameters**

128 A stable equilibrium age distribution (with 2017 as the baseline year) and constant mortality
129 hazards for each age group were assumed, using data from the US Census Bureau website
130 (<https://www.census.gov/>). Since the implied growth rate was insignificant, constant population
131 was assumed over the analysis time horizon to reduce model complexity.

132 **Contact mixing matrix**

133 Mixing patterns among the population impact the transmission dynamics of an infectious
134 pathogen. Mixing patterns from Prem *et al.* [9] were derived to create the 6-age group contact
135 matrix (see Section 3.1.3 of the Supplementary Appendix). Although transmission among adults
136 was allowed, it was assumed that there was no transmission of SP from adults to the pediatric
137 population [10].

138 **Vaccine parameters**

139 The model assumed full vaccine compliance (i.e., 3+1 doses in pediatric population) and used
140 the respective age-specific observed vaccine coverage rates (VCRs) over the historical period
141 and anticipated VCRs for projections. VCR in each vaccine-target age group is discussed in
142 Supplementary Appendix. In the model, a distinction between two types of vaccine effectiveness
143 (VE) was made: VEC against carriage acquisition and VED against pneumococcal disease (VED
144 was unique for each disease outcome of IPD, AOM, and NBPP). VEs vary by vaccine (PCV13,
145 PCV15, PCV20, and PPSV23), STC, and age group. VEDs against NBPP and AOM can be seen
146 in Supplementary Tables S10 and S11. VECs were calibrated in the model.

147 STC- and age-specific VEds against IPD of all vaccines considered in the model were based on
148 clinical trials and real-world-evidence studies (Table 1). VEd of PCV13 against STC1-type (i.e.,
149 PCV7 STs) IPD in children was assumed to be identical to published PCV7 VEd [11]. ST-
150 specific VEds for the additional PCV13 serotypes were taken from Moore *et al.* [12]. Since
151 VEds within an STC may vary, VEds for each STC in children were estimated as the incidence-
152 weighted average of individual VEds. There is no consensus regarding the VEd of PCV13 on
153 serotype 3 [13]. Despite high pediatric coverage levels, real world evidence reveals that the long-
154 term impact of PCV13 has had little to no effect on population-level ST3 incidence. Therefore,
155 VEd against ST3 in the base case was assumed to be equal to the left end point of the 95%
156 confidence interval from Moore *et al.* [12].

Table 1. Vaccine effectiveness against IPD by age and serotype class. (PCV20 was only considered for adult vaccination).

		Age (years)			
PCV13	STC	0-17	18-49	50-64	65+
	1	0.96	0.739	0.713	0.677
	2	0.87	0.739	0.713	0.677
	3	0.303*	0.256	0.247	0.235
	4	0.883	0.739	0.713	0.677
	5	0.86	0.739	0.713	0.677
	6-11	0			
PCV15	1-5	Identical to PCV13 VE			
	6	0.86	0.739	0.713	0.677
	7-11	0			
PCV20	1-6	Identical to PCV15 VE			
	7	0			
	8, 9	NA	0.739	0.713	0.677
	10, 11	0			
PPSV23	1-4, 6-9	NA	0.585	0.559	0.521
	5,10,11	NA	0	0	0

IPD: Invasive Pneumococcal Disease; STC: Serotype Class; NA: Not Applicable;

PCV13: 13-valent pneumococcal conjugate vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PCV20: 20-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes;

*: left end point of 95%CI.

157 Populations in each adult age group include those at low risk for pneumococcal disease (healthy
158 individuals) as well as those with increased risk due to immunocompromising conditions. The
159 VEd of PCV13 for IPD in adults who are at-risk was based on Bonten *et al.* [14] and Leidner *et*
160 *al.* [15], and VEd of PPSV23 was based on [15]. These were incorporated into the age-based
161 population-level VEds based on risk distribution by age (Table S9).

162 Equivalency was assumed for the new vaccines, which is that new PCVs with additional STs (e.g
163 PCV15 and PCV20) have equivalent VEds as previous PCVs (PCV13) for shared serotypes.
164 Overall VEd of PCV13 [12] was used as VEd of PCV15 against STC6-type IPD in children.
165 PCV13 VEd in adults was not ST-specific and was extended to additional PCV15 and PCV20
166 STCs (Table 1).

167 In a scenario analysis STC-specific VEd for PCV15 was based on immune response of PCV15
168 relative to PCV13. Results of this scenario analysis are presented in the Supplementary
169 Appendix.

170 It was assumed that mean duration of protection from any PCV was 10 years, while PPSV23 was
171 assumed to have a mean duration of protection of 7.5 years [15].

172 **Carriage clearance rates**

173 Annual carriage clearance rates for a given serotype were calculated as the inverse of carriage
174 duration. A literature review was performed to collect data on age and serotype-specific carriage
175 durations. For each age-STC combination the total carriage duration across studies was divided
176 by the total population across studies and normalized by age group. More details on these
177 derivations are available in Section 3.2.4.1.1 of the Supplementary Appendix.

178 **Model calibration**

179 To infer the values of the age- and STC-specific probability of acquisition, age- and STC-
180 specific case-carrier ratios, STC-specific competition parameters, and the STC-specific V_{Ec} for
181 the VTs, the model was calibrated to historical US IPD incidence data from 2000–2019.
182 Pneumococcal dynamics were impacted from the COVID-19 pandemic [16] through reduced
183 transmission due to non-pharmaceutical interventions and disruption of routine healthcare
184 services including vaccination. Since the model does not account for such dynamics, data after
185 2019 was not included in model calibration. Calibration methodology and detailed results are
186 described further in the Supplementary Appendix.

187 **Calibration target**

188 Age-stratified STC-specific IPD incidence per 100,000 in the US from 1998-2019 was used as
189 calibration target. These incidence data were generated by Merck & Co., Inc., Rahway, NJ, USA using
190 serotype distribution data from Active Bacterial Core surveillance (ABCs), Centers for Disease Control
191 and Prevention (CDC), and the annual IPD incidence from the annual CDC surveillance reports [17] and
192 may differ from data published by the CDC.

193 For calibration to NBPP data, pediatric NBPP incidence per 100,000 from 1998–2018 was
194 obtained from Hu *et al.* [18]. To obtain the counterpart data in adults, all-cause pneumonia
195 (ACP) incidence was acquired from Truven MarketScan Commercial Claims and Encounters
196 (January 1, 2012 to December 2020). It was assumed that 11% of ACP had pneumococcal
197 etiology—NBPP—in US adults [19]. For pediatrics, it was assumed that ST distribution for
198 NBPP followed that of IPD. For adults, the proportion of NBPP attributable to STCs was
199 calculated using data from two recent studies [20, 21] and the STC- and age-specific data was
200 constructed (see Section 5.1 of Supplementary Appendix for additional details).

201 For AOM calibration, pediatric all-cause AOM incidence per 100,000 from 1998-2018 was
202 obtained from Hu *et al.* [22] of which 23.8% was pneumococcal attributable [23]. Studies with
203 ST distribution information for AOM cases [23, 24, 25] were used to construct the STC- and
204 age-specific data (see Section 5.2 in Supplementary Appendix for additional details).

205 Using the carriage prevalence profile that corresponded to calibrated IPD incidence, case-carrier
206 ratios for NBPP and AOM were then calibrated using the historical incidence of each
207 manifestation. Details on NBPP and AOM calibration, procedure, and results are provided in the
208 Supplementary Appendix.

209 **Model projections**

210 The calibrated model was then used to compare pneumococcal disease burden assuming either
211 pediatric PCV13 or PCV15 vaccination. In adults, both PCV15 with PPSV23 or PCV20 have
212 been recommended for use [26]. A hypothetical combination of these vaccines was constructed.
213 In addition, given the historic practice, we assumed that healthcare providers may continue to
214 administer PPSV23 alone. Therefore, to design an adult vaccination scenario (which would be
215 kept same while comparing the two pediatric vaccination scenarios) it was assumed that of the
216 vaccinated US adults 80% receive PCV20, 10% receive PCV15+PPSV23, and 10% receive
217 PPSV23 alone. Since adult vaccination was identical between these two scenarios, the
218 differences in model outcomes were solely caused by pediatric vaccination.

219 The two scenarios are summarized below:

- 220 1. Scenario PCV13: Children 0-2 receive PCV13 according to assumed VCR. Given
221 assumed VCR among adults 18+, 80% receive PCV20, 10% receive PPSV23, and 10%
222 receive PCV15+PPSV23.

223 2. Scenario PCV15: Children 0-2 receive PCV15 according to assumed VCR. Given
224 assumed vaccination coverage among adults 18+, 80% receive PCV20, 10% receive
225 PPSV23, and 10% receive PCV15+PPSV23.

226 Results

227 IPD data calibration results

228 The model was able to capture historical trends in each of the STCs for each age group (Fig 2,
229 3). Before the introduction of a PCV in the US, PCV7 serotypes (STC1) dominated the IPD
230 landscape. However, after the introduction of PCV7 in 2000 and prior to the introduction of
231 PCV13 in 2010, replacement occurred, with the additional PCV13 (excluding ST3) serotypes
232 increasing in incidence. This replacement behavior was captured by the model due to the
233 inclusion of a competition parameter. In 2010 PCV13 was introduced and all PCV13 STCs, other
234 than ST3, declined. ST3, both in the model and data, remained relatively constant across the
235 calibration period. Following PCV13 introduction, all non-vaccine STCs trended upward.
236 Prior to PCV7, STC1 outcompeted other STs, but following PCV7 introduction, and the
237 reduction in STC1 STs, STCs 4,7, &10 were able to spread due to the reduced competitive
238 pressure from STC1 STs

239 Fig 2. Calibrated versus IPD incidence per 100,000 over time in children age groups. Dashed lines: data; Solid lines: model
240 outcome.

241 Fig 3. Calibrated versus IPD incidence per 100,000 over time in adult age groups. Dashed lines: data; Solid lines: model
242 outcome.

243

IPD = invasive pneumococcal disease; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes; V116 = an investigational 21-valent pneumococcal conjugate vaccine.

244

245 Years of real-world data following the introduction of new vaccines will be necessary to estimate
246 how new vaccine type STs, such as 22F and 33F (STC6) compete and interact with other STCs.

247 The model estimated age- and serotype-specific V_{Ec}, which revealed PCV7 to have a greater
248 impact against the 7 serotypes it targeted than PCV13 had on the additional 6 serotypes it
249 targeted (Table S18). The model also calculated age- and serotype-specific case-to-carrier ratios
250 for IPD (Table S17). Results indicated that these case-carrier ratios were highest in the youngest
251 and oldest age groups.

252 Following the calibration of the model to IPD incidence, which generated age- and STC-specific
253 carriage acquisition rates, the model was then calibrated to estimate the age- and STC-specific
254 case-carrier ratios for each of AOM and NBPP. The model captured changes in the serotype
255 distribution associated with AOM after different vaccine introductions, such as the decline of 5
256 of the additional serotypes included in PCV13 (excluding STC3) (Figure S14). Similarly, the
257 model replicated reductions in PCV7 STs in 2000 and STC4 (7F, 19A) in 2010 in pediatric
258 NBPP following the introduction of PCV7 and PCV13 (Figure S13).

259 **Epidemiological projections**

260 The calibrated model was used to make projections for the two scenarios described above (Fig
261 4). Projections revealed that PCV15 prevented more cases of IPD, AOM, and NBPP than PCV13
262 across all age groups. The reduced incidence of IPD in pediatric age groups under the PCV15
263 scenario reflected the direct and indirect benefit due to the added vaccine type serotypes 22F and

264 33F, while the lower incidence in adult age groups was due to indirect protection (i.e., herd
265 immunity) from the pediatric population. It was estimated that over 10 years, PCV15 would
266 reduce about 6% more cases of IPD when compared to PCV13. This includes around 12.76%
267 more cases averted in children under 2 and 4.82% more cases averted in adults over the age of
268 65.

269 **Fig 4. IPD incidence per 100,000 projected by the calibrated model.** Top: IPD burden, children < 5; Bottom: Overall IPD burden
270 by age group. Vaccination in adults: 80% receive PCV20, 10% receive PPSV23, and 10% receive PCV15+PPSV23. Vaccine
271 coverage used in these projections is given by Figure S6. Reduced IPD incidence in adults is a result of indirect protection of
272 pediatric PCV15 vaccination.

273 IPD = invasive pneumococcal disease; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal;
274 STs = serotypes; VE = vaccine effectiveness

275 The model estimated that after 10 years, compared to PCV13, PCV15 will also reduce the
276 number of NBPP cases by 5.5% and the number of AOM cases by about 3%.

277 **Projected IPD STC distribution**

278 Fig 5 shows the pre-PCV, 2019, and 10 year-projections of IPD incidence. By 2019, PCV7 and
279 PCV13 reduced overall IPD, however ST-distributions shifted with NVTs replacing VTs over
280 this same period. The third column shows the projected shift in this distribution following 10
281 years of PCV15 utilization. STs 22F and 33F (PCV15 non-PCV13) are diminished with PCV15.
282 There is a clear shift from vaccine-types towards NVTs (Other STs) through ST replacement.
283 Since PCV20 was implemented in adult age groups (18 and above) in projection period, IPD in
284 the PCV20 non-PCV15 STC was reduced in adults.

Fig 5. IPD incidence (cases per 100,000) attributed to each STC grouped by vaccine in each model age group. Model calibrated STC distributions and data at the start and end of calibration period (2000 and 2019 respectively), and model projected STC distributions after 10 years of PCV15 in children.

285 IPD = invasive pneumococcal disease; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent pneumococcal
286 conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide
287 vaccine; ST3 = serotype 3; STCs = serotype classes

288 Discussion

289 An age-structured dynamic model of pneumococcal carriage transmission was developed to
290 evaluate the epidemiological impact of age-based vaccine policies on pneumococcal diseases.
291 Serotypes were divided into serotype classes (STCs) which allowed disease incidence to be
292 examined by each age and STC combination.

293 The model was calibrated to the historical age-specific US IPD incidence data from 2000 to 2019
294 and used to project future outcomes under different vaccine strategies. The results of this
295 calibration revealed age- and serotype-specific carriage acquisition probabilities, competition
296 parameters between STCs, age- and serotype-specific vaccine efficacies against carriage, and
297 age- and serotype specific case-to-carrier ratios for invasive and non-invasive pneumococcal
298 disease (IPD, NBPP, and AOM). Calibrated values fell within the range of published estimates
299 where available or were aligned with calibration estimates of published models.

300
301 Probability of carriage acquisition per contact with a colonized individual, which is an age- and
302 STC-specific parameter, was highest in the youngest and oldest age groups due to weak immune
303 systems (i.e., immature in children [27] and deficient due to age in older adults [28]). This
304 implies that children in the first two age groups (aged 0-4) and individuals in the oldest age
305 group (aged 65+) are most likely to acquire carriage upon contact with a colonized individual of
306 any age. These results are consistent with other literature (for example, see [29, 30, 31]). Case-
307 to-carrier ratios for IPD followed a similar pattern, with those in the youngest and oldest age

308 groups most likely to develop disease from carriage acquisition [32]. Calibration estimates of
309 case-to-carrier ratios for IPD also fall within the range of published estimates [32, 33, 34, 35].
310 The calibrated competition parameter estimates correctly reflected the ST replacement in the US
311 whereby NVTs increased to fill the niche that arose due to target STs declining following PCV7
312 and PCV13 implementation. Modeling literature highlights the role of ST competition [36] and
313 some pneumococcal transmission models have included this feature at a higher level or in some
314 aggregation [37, 38, 39]. However, calibrated ST competition between PCV7 STs against non-
315 PCV7 STs, and PCV13 STs against non-PCV13 STs, to our knowledge, has not been examined
316 at such granularity before.

317 Our parameter estimates of STC-specific V_{Ec} aligned with those reported in published literature
318 [40, 41]. Like pneumococcal disease, PCVs are also less protective against ST3 acquisition [42].
319 This is evident from the relatively low calibrated V_{Ec} against ST3 which was also the case with
320 other published model calibrations that reported ST-specific V_{Ec} [29]. Additionally, V_{Ec} in
321 adults is lower than the respective STC-specific V_{Ec} in children. Since carriage acquisition is a
322 precursor for pneumococcal disease, protection against acquisition is the first level of defense
323 that PCVs offer; reduction in acquisition will lead to reduction in disease.

324 Since dynamic transmission models estimate the time-dependent dynamics of population-level
325 susceptibility along with factors that affect the transmission rate (e.g., vaccination status and
326 carriage acquisition in response to mixing patterns), they are well suited to provide insights into
327 the indirect protection provided from interventions, such as including vaccination. Our model
328 assumes no transmission from adults to children [10] so there is no indirect effect of vaccinating
329 adults on children. Indirect protection of pediatric vaccination on adults which has been observed
330 in programs where pneumococcal vaccines have been implemented in pediatric programs [43],

331 can be analyzed in detail using this model. Here, identical vaccination strategies in adults were
332 kept and the two different vaccination programs in children, PCV13 versus PCV15, were
333 compared. Due to indirect protection (i.e., herd immunity), the implementation of PCV15 in
334 pediatrics led to additional reductions in adult disease attributed to 22F and 33F.

335 The model does have some limitations. First, because of lack of data to estimate some parameters
336 such as STC-specific probability of SP acquisition we inferred the values of some of these
337 parameters by calibrating the model outcomes to historical data. Second, certain serotypes, such
338 as serotype 3, have evolved under pressure from vaccination [44, 45] but the model does not
339 account for such evolution, assuming the same properties of STCs throughout the calibration and
340 projection horizons. It is also worth highlighting that including several STs into a single STC
341 entails strong assumption that STs in the same STC have identical properties.

342 The flexibility and accuracy of the model demonstrates promise for future adaptations in other
343 settings, where local pneumococcal epidemiology may vary, such as different age-reporting,
344 vaccine history, vaccine dosing, vaccine efficacies, different STs of interest, or different policy
345 questions. The model implemented here focused on epidemiological outcomes, but in future
346 work the model could additionally be used to evaluate the cost-effectiveness of different
347 vaccines or vaccination strategies. Understanding that certain viral pathogens, such as respiratory
348 syncytial virus, influenza, and human metapneumovirus may facilitate IPD [46, 47, 48, 49],
349 historical data from these pathogens can also be included into the model to capture some of the
350 unexplained inter-annual variation in IPD incidence.

351 **Funding:** This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co.,
352 Inc., Rahway, NJ, USA.

353 **Conflicts of Interest:** Tufail M Malik, Kevin M Bakker, Rachel J Oidtmann, Oluwaseun Sharomi
354 and Elamin H Elbasha are employees and stockholders of Merck Sharp & Dohme LLC, a
355 subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

356 **References**

357

- [1] "Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae," Centers for Disease Control and Prevention, 1998-2021. [Cited 2024 Apr 17]. Available: https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2021.pdf.
- [2] Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, Rudan I, Black R and Knoll MD, "Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15," *Lancet Glob Health*, vol. 6, pp. e744-e757, 2018.
- [3] Hausdorff W, Feikin D and Klugman K, "Epidemiological differences among pneumococcal serotypes," *Lancet Infect Dis*, vol. 5, pp. 83-93, 2005.
- [4] Jagne I, von Mollendorf C, Wee-Hee A, Ortika B, Satzke C and Russell F, "A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age," *Vaccine*, vol. 41, pp. 3028-37, 2023.
- [5] Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien K and PneumoCarr, "The fundamental link between pneumococcal carriage and disease," *Expert Rev Vaccines*, vol. 11, pp. 841-55, 2012.
- [6] Gierke R, Wodi AP and Kobayashi M, "Epidemiology and Prevention of Vaccine-Preventable Diseases," Centers for Disease Control and Prevention, 18 August 2021. [Cited 2024 Apr 17]. Available: <https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html>.
- [7] Weinberger DM, Malley R and Lispitch M, "Serotype replacement in disease after pneumococcal vaccination," *Lancet*, vol. 6736, no. 10, pp. 1962-73, 2011.
- [8] Ouldali N, Varon E, Levy C, Angoulvant F, Georges S, Ploy M-C, Kempf M and Cremniter J, "Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study," *Lancet Infect Dis*, vol. 21, pp. 137-47, 2021.
- [9] Prem K, Cook A and Jit M, "Projecting social contact matrices in 152 countries using contact surveys and demographic data," *PLoS Comput Biol*, vol. 13, 2017.

- [10] Althouse B, Hammitt L, Grant L, Wagner B, Reid R, Larzelere-Hinton F, Weatherholtz R, Klugman K, Rodgers G and O'Brien K, "Identifying transmission routes of *Streptococcus pneumoniae* and sources of acquisitions in high transmission communities," *Epidemiol Infect*, vol. 145, no. 13, pp. 2750-8, 2017.
- [11] Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist A-C, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP and Zell ER, "Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study," *Lancet*, vol. 368, no. 9546, pp. 1495-502, 2006.
- [12] Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, Thomas A, Guevara RE and Motala T, "Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study," *Lancet Respir Med*, vol. 4, no. 5, pp. 399-406, 2016.
- [13] T Pilishvili, "13-valent pneumococcal conjugate vaccine (PCV13) effects on disease caused by serotype 3 (Advisory Committee on Immunization Practices)," 28 February 2019. [Cited 2024 Apr 17]. Available: <https://stacks.cdc.gov/view/cdc/78091>.
- [14] Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. "Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults," *N Engl J Med*, vol. 372, no. 12, pp. 1114-25, 2015.
- [15] Leidner A, "Summary of three economic models assessing pneumococcal vaccines in US adults (ACIP Presentation Slides: September 29, 2021 Meeting)," 2021. [Cited 2024 Apr 17]. Available: <https://www.cdc.gov/vaccines/acip/meetings/slides-2021-09-29.html>.
- [16] Dagan R, Danino D and Weinberger D, "The Pneumococcus-Respiratory Virus Connection- Unexpected Lessons From the COVID-19 Pandemic," *JAMA Netw Open*, vol. 5, 2022.
- [17] "Centers for Disease Control and Prevention," Active Bacterial Core surveillance. [Cited 2024 Apr 17]. Available: <https://www.cdc.gov/abcs/reports-findings/surv-reports.html>.
- [18] Hu T, Sarpong EM, Song Y, Done N, Liu Q, Lemus-Wirtz E, Signorovitch J, Mohanty S and Weiss T, "Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis," *Pneumonia (Nathan)*, vol. 15, no. 1, 2023.
- [19] Choi MJ, Song JY, Cheong HJ, Jeon JH, Kang SH, Jung EJ, Noh JY and Kim WJ, "Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes," *J Infect Chemother*, vol. 21, no. 9, pp. 672-9, 2015.
- [20] Isturiz R, Grant L and Gray S, "Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults," *Clin Infect Dis*, vol. 73, no. 7, pp. 1216-22, 2021.

- [21] Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, Overcash JS, Oliva SP and File T, "Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia," *Vaccine*, vol. 37, no. 25, pp. 3352-61, 2019.
- [22] Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, Lemus-Wirtz E, Signorovitch J, Sarpong E and Weiss T, "Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018," *BMC Infect Dis*, vol. 22, no. 1, 2022.
- [23] Kaur R, Fuji N and Pichichero ME, "Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019," *Eur J Clin Microbiol Infect Dis*, vol. 41, no. 1, pp. 37-44, 2022.
- [24] Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R and Keegan E, "Pneumococcal serotypes from acute otitis media in rural Kentucky," *Pediatr Infect Dis J*, vol. 21, no. 9, pp. 859-65, 2002.
- [25] Casey JR, Adlowitz DG and Pichichero ME, "New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine," *Pediatr Infect Dis J*, vol. 29, no. 4, pp. 304-9, 2010.
- [26] Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA and Cohen AL, "Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022," *MMWR*, vol. 71, pp. 1174-81, 2022.
- [27] Lambert L and Culley F, "Innate Immunity to Respiratory Infection in Early Life," *Front Immunol*, vol. 8, 2017.
- [28] Krone C, van-de-Groep K, Trzcinski K, Sanders E and Bogaert D, "Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions," *Lancet Respir Med*, vol. 2, pp. 141-53, 2014.
- [29] Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A, Slack M and Farkouh R, "Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK," *Epidemiol Infect*, vol. 146, no. 14, pp. 1797-806, 2018.
- [30] Mosser JF, Grant LR, Millar EV, Weatherholtz RC, Jackson DM, Beall B, Craig MJ, Reid R, Santosham M and O'Brien KL, "Nasopharyngeal carriage and transmission of *Streptococcus pneumoniae* in American Indian households after a decade of pneumococcal conjugate vaccine use," *PLoS One*, vol. 9, 2014.
- [31] Melegaro A, Gay N and Medley G, "Estimating the transmission parameters of pneumococcal carriage in households," *Epidemiol Infect*, vol. 132, pp. 433-41, 2004.
- [32] Choi Y, Jit M, Flasche S, Gay N and Miller E, "Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales," *PLoS One*, vol.

7, no. 7, p. e39927, 2012.

- [33] Southern J, Andrews N, Sandu P, Sheppard CL, Waight PA, Fry NK, Van Hoek AJ and Miller E, "Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England," *PLoS One*, vol. 13, 2018.
- [34] Yildirim I, Little B, Finkelstein J, Lee G, Hanage W, Shea K and Pelton S, "Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts' children to relatively low invasiveness," *Vaccine*, vol. 35, pp. 4002-9, 2017.
- [35] Lochen A and Anderson R, "Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations," *Clin Microbiol Infect*, vol. 26, no. 1, pp. 60-70, 2020.
- [36] Lipsitch M, "Vaccination against colonizing bacteria with multiple serotypes," *Proc Natl Acad Sci U.S.A.*, vol. 94, no. 12, pp. 6571-6, 1997.
- [37] Melegaro A, Choi Y, George R, Edmunds W, Miller E and Gay N, "Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease," *BMC Infect Dis*, vol. 90, p. 10, 2010.
- [38] Masala G, Lipsitch M, Bottomley C and Flasche S, "Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination," *J R Soc Interface*, vol. 14, no. 136, 2017.
- [39] De-Cao E, Melegaro A, Klok R and Postma M, "Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling," *PLoS One*, vol. 9, no. 4, p. e89415., 2014.
- [40] Gjini E, "Geographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7," *Sci Rep*, vol. 7, no. 1, p. 3049, 2017.
- [41] Rinta-Kokko H, Dagan R, Givon-Lavi N and Auranen K, "Estimation of vaccine efficacy against acquisition of pneumococcal carriage," *Vaccine*, vol. 27, no. 29, pp. 3831-7, 2009.
- [42] Lapidot R, Shea K, Yildirim I, Cabral H, Pelton S and The Massachusetts Department of Public Health, "Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts," *Pathogens*, vol. 9, 2020.
- [43] Miller E, Andrews N, Waight P, Slack M and George R, "Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study," *Lancet Infect Dis*, vol. 11, pp. 760-8, 2011.
- [44] Groves N, Sheppard CL, Litt D, Rose S, Njoku ASN, Rodrigues S, Amin-Chowdhury Z, Andrews N, Ladhani S and Fry NK, "Evolution of *Streptococcus pneumoniae* Serotype 3 in England and Wales: A

Major Vaccine Evader," *Genes (Basel)*, vol. 10, 2019.


- [45] Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A, Pollard AJ, et al., "Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci," *PLoS Pathog*, vol. 14, 2018.
- [46] Ben-Shimol S, Greenberg D, Hazan G, Shemer-Avni Y, Givon-Lavi N and Dagan R, "Seasonality of both bacteremic and nonbacteremic pneumonia coincides with viral lower respiratory tract infections in early childhood, in contrast to nonpneumonia invasive pneumococcal disease, in the pre-pneumococcal conjugate vaccine era," *Clin Infect Dis*, vol. 60, no. 9, pp. 1984-7, 2015.
- [47] Weinberger DM, Grant LR, Steiner CA, Weatherholtz R, Santosham M, Viboud C and O'Brien KL, "Seasonal Drivers of Pneumococcal Disease Incidence: Impact of Bacterial Carriage and Viral Activity," *CID*, vol. 584, 2014.
- [48] Weinberger DM, Harboe ZB, Viboud C, Krause TG, Miller M, Mølbak K and Konradsen HB, "Serotype-specific effect of influenza on adult invasive pneumococcal pneumonia," *J Infect Dis*, vol. 208, no. 8, pp. 1274-80, 2013.
- [49] Stensballe LG, Hjuler T, Andersen A, Kaltoft M, Ravn H, Aaby P and Simoes EAF, "Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study," *Clin Infect Dis*, vol. 46, no. 8, pp. 1165-71, 2008.










358


359

360 **Supporting information**


361 **S1 Text. Supplementary Appendix**









PCV13-type IPD in <2




PCV15 non-PCV13-type IPD in <2




Non-PCV15-type IPD in <2




Overall incidence in <2



Overall incidence in 2-4



Overall incidence in 65+



— PCV15 in children <2
 - - - PCV13 in children <2

■ Data
 ■ Strategy PCV13
 ■ Strategy PCV15

